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Abstract
Background: Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a
broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The
transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin
derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine
kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).
Methods: OCT1 (SLC22A1) and OCT3 (SLC22A3) mRNA expression was measured in primary human HCC and
corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53). Protein expression was
determined by western blot analysis and immunofluorescence. Data were correlated with the clinicopathological
parameters of HCCs.
Results: Real time PCR showed a downregulation of SLC22A1 and SLC22A3 in HCC compared to TST (p ≤ 0.001). A
low SLC22A1 expression was associated with a worse patient survival (p < 0.05). Downregulation was significantly
associated with advanced HCC stages, indicated by a higher number of T3 tumors (p = 0.025) with a larger tumor
diameter (p = 0.035), a worse differentiation (p = 0.001) and higher AFP-levels (p = 0.019). In accordance, SLC22A1
was less frequently downregulated in tumors with lower stages who underwent transarterial chemoembolization (p
< 0.001) and liver transplantation (p = 0.001). Tumors with a low SLC22A1 expression (< median) showed a higher
SLC22A3 expression compared to HCC with high SLC22A1 expression (p < 0.001). However, there was no significant
difference in tumor characteristics according to the level of the SLC22A3 expression.
In the western blot analysis we found a different protein expression pattern in tumor samples with a more diffuse
staining in the immunofluorescence suggesting that especially OCT1 is not functional in advanced HCC.
Conclusion: The downregulation of OCT1 is associated with tumor progression and a worse patient survival.
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Hepatocellular carcinoma (HCC) is one of the most
common human malignancies worldwide with growing
numbers of patients frequently leading to death [1]. In
the majority of cases tumors grow multifocal and show
a high rate of recurrence with a poor prognosis [2]. In
general, HCCs do not respond to classical chemothera-
peutics. Treatment options, especially with regard to a
systemic therapy, are very limited. Therefore, new mar-
kers and therapeutic usable targets are urgently needed.
Transporters contribute to the survival of a single cell
in a higher organism and mediate the interaction
between cells and their environment. Moreover, they
play an important role in the cellular uptake of antican-
cer drugs and the development of multidrug resistance.
The three organic cation transporters OCT 1
(SLC22A1), OCT2 (SLC22A2) and OCT3 (synonym:
extraneuronal monoamine transporter–EMT)
(SLC22A3) belong to the amphiphilic solute facilitator
(ASF) family of integral transmembrane proteins and
are involved in many metabolic processes and
detoxification.
T h er o l eo fO C T si nm e t a b o l i s mi st h eu p t a k e ,i n t r a -
cellular inactivation and biliary or urinary excretion of a
broad spectrum of endogenous (e.g. catecholamines)
and exogenous substrates (e.g. metformine, betablockers,
etc.) as well as anticancer drugs (e.g. platin derivatives)
[3-11].
Therefore, OCTs became pharmaceutically interesting:
the OCT1 activity was reported to correlate with the
sensitivity of tyrosine kinase inhibitors (TKI), e.g. imati-
nib, in patients with chronic myeloid leukemia (CML)
[12-14]. Furthermore, OCTs are determinants of the
cytotoxicity of platin derivates, which is relevant for the
responsiveness towards platin-containing chemothera-
pies [11].
Since important metabolic pathways are secured, the
OCTs have overlapping substrate specificities and tissue
expression patterns. In human OCT1 is mainly
expressed in the liver, OCT 2 in the kidney, whereas
OCT3 is widely distributed in many tissues.
Interestingly, OCT1 was reported to be not relevantly
expressed in liver cancer cell lines [15]. Therefore, the
question arose whether OCT1 and OCT3, which are
physiologically expressed in the liver, are present in pri-
mary HCC.
The aim of our study was to elucidate the impact of
OCT expression on HCC and patient survival. Expres-
sion levels were measured in HCC and corresponding
non neoplastic tumor surrounding tissue (TST) and cor-
related with clinicopathological parameters and
outcomes.
Methods
Patient tissue samples
Normal liver tissue was obtained from 10 patients who
underwent liver biopsy for elevated liver enzymes but
showed completely normal histology. HCC tumor sam-
ples and corresponding TST were obtained from 53
patients undergoing liver resection or liver transplanta-
tion (LT) between 2006 and 2011 at the Department of
Hepatobiliary and Transplantation Surgery of the
Johannes Gutenberg University Mainz, Germany.
Informed consent was given by each patient. The study
followed the ethical guidelines of the Declaration of Hel-
sinki and was approved by the local ethics committee.
Liver tissues were immediately shock frozen after resec-
tion and underwent liquid nitrogen storage prior to ana-
lysis. All HCC were histological confirmed.
Culture of tumor cell lines
Hepatic tumor cell lines (HepG2, Hep3b, Huh6 and
Huh7) were cultured in DMEM/GlutaMax-1 (InVitro-
gen, Carlsbad, CA, USA) supplemented with 10% FCS
(PAA, Pasching, Austria) and 1% penicillin/streptomycin
(Cambrex, East Rutherford, NJ, USA). Cells were grown
at 37°C in 5% CO2 atmosphere in cell culture flasks and
medium was replaced every 2 days. Prior to mRNA iso-
lation, cells were removed from the flasks by 0.05% tryp-
sin/EDTA (PAA, Pasching, Austria) treatment. HEK 293
cells stably transfected with pcDNA3 OCT1 and
pcDNA3 OCT3 constructs were kindly provided by Dirk
Gründemann and served as positive control.
RNA isolation, RT-PCR and real-time RT-PCR analysis
RNA isolation of tumor cell lines was done using the
RNeasy Mini Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s recommendations. RNA from tis-
sue samples was extracted by the High Pure RNA Tis-
sue Kit (Roche, Mannheim, Germany). cDNA
preparation from total RNA was performed with 500 ng
RNA (20 μl total volume) using the iScript cDNA
Synthesis kit (Biorad, München, Germany). All kits
mentioned were used according to the manufacturer’s
recommendations. For semiquantitative RT-PCR analysis
1 μl (200 ng) of the cDNA was used as template for the
specific PCRs using Red Taq Ready Mix PCR Reaction
mix (Sigma, Munich, Germany). Primers applied were
GAPDH: forward 5’-AAT CCC ATC ACC ATC TTC
CA-3’, reverse 5’-TGT GGT CAT GAG TCC TTC CA-
3’ (318 bp fragment); OCT1 (SLC22A1): forward 5’-
GTG TGT AGA CCC CCT GGC TA-3’, reverse 5’-
GTG TAG CCA GCC ATC CAG TT-3’ (363 bp frag-
ment); OCT3 (SLC22A3): forward 5’-ATC GTC AGC
GAG TTT GAC CT-3’, reverse 5’-TTG AAT CAC GAT
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were as follows: initial denaturation (3 min 95°C) fol-
lowed by 36 cycles of denaturation (30s at 94°C),
annealing (1 min at 60°C), and elongation (1 min at 72°
C). After the last cycle, a final extension (10 min at 72°
C) was added, and thereafter, the samples were kept at
4°C. 20 μl of the products were run on a 1.5% agarose
gel stained by ethidium bromide, and analyzed under
UV light.
Quantitative analysis of OCT1 (SLC22A1)a n dO C T 3
(SLC22A3) transcripts was performed by real-time RT-
PCR. The Quantitect SYBR Green PCR Kit (Qiagen, Hil-
den, Germany) and validated primers of a Quantitect
Primer Assay with the primer sets HS_SLC22A1_1_SC
(OCT1; 120 bp fragment), HS_SLC220A3_1_SC (OCT3;
115 bp fragment) and HS_GAPDH_2_SG (GAPDH; 119
bp fragment) (Qiagen, Hilden, Germany) were used
according to the manufacturers instructions. For the
amplification, an initial denaturation at 95°C for 15 min,
followed by 15 s at 94°C, 30s at 55°C and 30s at 72°C
for 40 cycles was used. Samples were run on a LightCy-
cler
® 480 real-time PCR system (Roche, Mannheim,
Germany). The relative expression levels of OCT1
(SLC22A1)a n dO C T 3( SLC22A3)m R N Ai nH C Ca n d
TST were calculated by normalization to GAPDH gene
expression using the LightCycler
® 480 software Release
1.5.0. For examination of OCT1 (SLC22A1)a n dO C T 3
(SLC22A3) mRNA regulation, the relative mRNA
expression of tumor tissue (HCC) was related to the
relative mRNA expression of corresponding TST. The
median expression of this ratio (SLC22A1: 0.112;
SLC22A3: 0.658) was used to define a cut-off value to
subdivide tumor tissues into high or low expressing
HCCs.
Western blot analysis
Total protein extracts were prepared in sample buffer
pH 8.0 containing 20 mM Tris, 5 mM EDTA, 0.5% Tri-
tonX-100 and complete Mini, EDTA-free protease inhi-
bitors (1:25; Roche Diagnostics, Germany). For Western
blot analyses 60 μg of protein were loaded on a 12%
SDS-PAGE gel. The gel was transferred onto a nitrocel-
lulose transfer membrane (OPTITRAN BA-S85/What-
man) following separation. Mouse-anti-OCT1
monoclonal antibody (1:1000; Novus Biologicals, Little-
ton, CO, USA), rabbit-anti-OCT3 (1:2000; Lifespan
Biosciences, Seattle, WA, USA) polyclonal antiserum or
goat-anti-actin (1:10000; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) polyclonal antiserum were used
as primary antibody. Horseradish peroxidase (HRP)-con-
jugated anti-mouse, anti-rabbit or anti-goat IgG (DAKO
Cytomation, Hamburg, Germany) were used as second-
ary antibody at 1:10000 dilution. Protein bands were
visualized using Western Lightning
® Plus-ECL,
enhanced chemiluminescent substrate (Perkin Elmer,
Waltham, MA, USA).
Immunofluorescence
The localization of OCT1 in human HCC samples and
corresponding TST was analyzed on frozen sections by
immunofluorescence microscopy. Prior to staining sec-
tions were fixed for 20 min with 4% paraformaldehyde/
PBS at room temperature in a wet chamber. After fixa-
tion, cells were washed with TBS (pH 7.6)/0.1% Tween.
After preincubation with hydrogen peroxide for blocking
of endogenous peroxidase, endogenous biotin was
blocked with the Avidin-Biotin Blocking kit (Vector
Laboratories, Burlingame, CA, USA) and contaminating
proteins were inhibited by ROTI
®-Immunoblock solu-
tion (ROTH, Karlsuhe, Germany). Then, samples were
incubated with mouse-anti-human OCT1 (1:200; Novus
Biologicals, Littleton, CO, USA) as primary antibody.
After incubation with the secondary antibody (goat anti-
rabbit IgG-Biotin, 1:1000; DAKO Cytomation, Hamburg,
Germany), the TSA™ Cyanine system (Perkin Elmer,
Waltham, MA, USA) was added. For negative control
the primary antibody was omitted. The images were
evaluated under a fluorescence microscope (Olympus
BX51, Olympus U-RFL-T).
Statistical analysis
Data management and all statistical analyses were per-
formed with the SPSS program (IBM
® SPSS
® Version
19.0). For categorical variables, between-group differences
were analyzed by the chi-square or Fisher’s exact test. For
quantitative variables data were expressed as median and
range. If distribution was normal and sample sizes tested
sufficient, equality of variances was analyzed with the
Levene’s test and samples were compared using the paired
t-test. If variables were not normally distributed or sample
size was too small, we applied the Wilcoxon rank sum
nonparametric test. All tests were performed using a five
percent level of significance (two-sided). Overall survival
rates were calculated using the Kaplan-Meier method and
compared using the log-rank test.
Results
Expression of OCT1 (SLC22A1) and OCT3 (SLC22A3) mRNA
in liver cancer cell lines, normal liver and primary HCCs
To analyse the role of OCT1 and OCT3 in malignant
liver cells, we first studied the mRNA expression in four
different human liver cancer cell lines (HepG2, Hep3b,
Huh6, Huh7). RT-PCR using glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH)-normalized cDNAs
revealed that SLC22A1 and SLC22A3 transcripts were
completely absent in HepG2 and Huh6 cell lines and
only low expression levels could be detected in Hep3b
and Huh7 cell lines (Figure 1A). SLC22A1 mRNA was
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Page 3 of 10Figure 1 (A) mRNA expression (RT-PCR) of OCT1 (SLC22A1)a n dO C T 3( SLC22A3) in hepatic tumor cell lines (HepG2, Hep3b, Huh6,
Huh7) relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).( B) mRNA expression (RT-PCR) of OCT1 (SLC22A1) and OCT3
(SLC22A3) in normal liver tissue of 10 patients relative to GAPDH. (C) Exemplarily mRNA expression (RT-PCR) in eleven patients (1-11) with HCC
and the corresponding non neoplastic tumor surrounding tissue (TST). (D) Downregulation of OCT1 (SLC22A1) and OCT3 (SLC22A3) mRNA
expression in HCC (n = 53) compared to TST. (E) Individual OCT1 (SLC22A1) and OCT3 (SLC22A3) mRNA expression pattern in each patient (HCC
and according TST).
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Page 4 of 10almost absent in Huh7 cell lines. Therefore, these tumor
cell lines seemed not to be suited for the investigation
of SLC22A1 and SLC22A3 expression in vitro.
Then we investigated the mRNA expression of
SLC22A1 and SLC22A3 in healthy normal human
l i v e r( n=1 0 ) ,H C C( n=5 3 )a n dc o r r e s p o n d i n gT S T .
Normal liver served as control for the expression of
SLC22A1 and SLC22A3. Figure 1B representatively
shows the RT-PCR results of 10 normal and healthy
liver control samples. As expected, SLC22A1 mRNA
was strongly expressed in human liver tissue, whereas
SLC22A3 mRNA was expressed to a lower degree.
TST exhibited comparable expression of SLC22A1
and SLC22A3 mRNA with normal liver tissue. Differ-
ences in the expression between TST and cancerous
tissue of 11 patients are exemplarily shown in Figure
1C.
Real time data confirmed a strong downregulation of
SLC22A1 mRNA expression in HCC compared to corre-
sponding TST (p = 0.001; Figure 1D). SLC22A3 was also
found to be downregulated in primary HCC compared
to TST (p < 0.001). Individual expression patterns in
HCC and the corresponding TST are demonstrated in
Figure 1E. Details of clinical and pathological character-
istics of the patients and tumors were summarized in
Table 1 according to WHO specifications. Compared to
TST SLC22A1 mRNA was in average 2,3-fold (± 1,4-
fold) down-regulated in tumor tissue of most HCCs,
whereas downregulation of SLC22A3 mRNA was lower
(1,2-fold (± 1,2-fold)) (Figure 1C, D, E).
Reduced survival in patients with intratumoral OCT1
(SLC22A1) downregulation
According to the real time PCR results, we divided the
patients into two groups: a high expression group
(expression level ≥ median) and a low expression group
(expression level < median).
Considering the SLC22A1 mRNA expression, there
was a significantly reduced overall patient survival in
patients with a low SLC22A1 mRNA expression in HCC
(p < 0.05) (Figure 2A). Although OCT3 (SLC22A3)
mRNA expression was also downregulated (Figure 1D),
the overall survival rate of HCC patients with low
expression of SLC22A3 mRNA was not significantly dif-
ferent from that of patients with high SLC22A3 mRNA
expression (p = 0.27; Figure 2B).
Patient and tumor characteristics according to the OCT1
(SLC22A1) mRNA expression
Low OCT1 (SLC22A1) mRNA expression levels were
associated with advanced HCC stages as indicated by a
higher frequency of T3 carcinomas (p = 0.025) with a
larger tumor diameter (p = 0.035), a worse tissue dif-
ferentiation as indicatedb yg r a d i n g( p=0 . 0 0 1 )a n d
higher AFP-levels (p = 0.019). Tumor characteristics
according to the SLC22A1 mRNA expression are
s h o w ni nT a b l e2 .SLC22A1 was less frequently down-
regulated in tumors with lower stages who underwent
transarterial chemoembolization (p < 0.001) and liver
transplantation (p = 0.001). Tumors with a low
SLC22A1 expression (< median) showed a higher
SLC22A3 expression compared to HCC with high
SLC22A1 expression (p < 0.001). However, there was
no significance in tumor characteristics for the
SLC22A3 expression (Table 3).
Protein expression of OCT1 in human HCCs
To examine the protein expression of the transporters
in HCC we performed western blot analysis. Figure 3
shows that the downregulation of the transporters,
especially OCT1, as measured in the RT-PCR (Figure
3A) correlates well with the corresponding protein
levels (Figure 3B). Becaus eo ft h ei m p a c to fO C T 1o n
tumor characteristics and patient survival we focused
on this transporter. To identify the localization of
OCT1 in tumor tissue, we subsequently evaluated pro-
tein expression by fluorescence microscopy (Figure 3C,
3D). In normal liver we detected a membranous stain-
ing (Figure 3C). In contrast, in HCC OCT1 protein
was not predominantly localized on the cell membrane
of cancerous hepatocytes, but was also present in the
cytoplasm (Figure 3D), suggesting the presence of non-
functional OCT1 protein with abrogated transport
function in tumor tissue.
Table 1 Patients and tumor characteristics
Characteristics
n5 3
Median follow-up in days (range) 434 (22-1645)
Male/female (n) 46/7
Median age in years (range) 67 (35-93)
1-3 nodules/multiple nodules (specimen) 36/17
Tumor diameter < 3 cm/> 3 cm 19/34
Median tumor diameter in cm (range) 5.0 (0.1-30)
T classification: T1/T2/T3 (specimen) 18/20/15
Grading: G1/G2/G3/Gx 11/31/10/1
AFP > 100/< 100 * 11/40
Angioinvasion yes/no
# 11/38
Child A/B/C/no cirrhosis 19/4/7/23
Underlying disease (HCV/HBV/alcoholic/others/unknown) 10/9/
4/15/15
Pretreatment with chemoembolization yes/no 20/33
Liver transplantation/resection 20/33
* 2 unknown
# 4 unknown
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OCTs have been extensively studied in many tissues and
tumor cell lines, but only few data exist about the pre-
sence and their role in human malignancies. In colorec-
tal cancer, Zhang et al. found a mRNA expression of
OCT2 (SLC22A2) in tumor samples, whereas this trans-
porter was not expressed in normal colon tissue [11].
SNPs in OCT3 (SLC22A3) were reported to contribute
to the risk of distal colon cancer in an Asian population
[16].
To our knowledge, this is the first study analyzing the
expression profiles of the OCTs in a larger series of
human hepatocellular carcinomas with direct correlation
to clinical and tumor-specific data.
The human HCC samples analyzed, revealed different
intensities of OCT1 (SLC22A1)a n dO C T 3( SLC22A3)
expression ranging from absent to strong. We did not
examine OCT2 in light of the absent to very rare and
low expression in the human liver. Expression rates in
RT-PCR were too low to establish meaningful statistical
results.
We showed a significant downregulation for both
transporters in HCC compared to the corresponding
TST (p ≤ 0.001). Downregulation of SLC22A1 mRNA
expression in primary human HCC is in line with pre-
viously published microarray findings by Park et al.,
where SLC22A1 showed a significantly reduced expres-
sion in HCC [17].
Our results provide first evidence that the downregu-
lation of SLC22A1 mRNA expression is associated with
advanced tumor stages and worse patient survival
(Table 2 Figure 2A). Furthermore, these tumors had
significantly higher T values (p = 0.025), G values (p =
0.001) and median tumor diameters (p = 0.035, Table
2). In tumors with lower stages, who underwent trans-
arterial chemoembolization and liver transplantation,
SLC22A1 was less frequently downregulated (p <
0.001). In our center transarterial chemoembolization
is performed with lipiodol (20 mL) and mitomycin c
( 1 0m gi n2 0m Lw a t e r )e v e r ys i xw e e k su n t i lt r a n s -
plantation. Both substances are not known to be sub-
strates for OCTs. The response to transarterial
chemoembolization is discussed to represent a biologi-
cal selection criterion for patients with HCC during
the waiting time for liver transplantation [18]. Whether
OCT1 might be a molecular marker involved in
mechanisms influencing the response to transarterial
chemoembolization or a marker to predict the tumor
biology and the risk of recurrence after liver transplan-
tation remains to be determined.
Figure 2 (A) Survival of HCC patients according to the
intratumoral OCT1 (SLC22A1) mRNA expression (real time
data). Downregulation of OCT1 is associated with a significantly
worse patient survival (p < 0.05). (B) Survival of HCC patients
according to the intratumoral OCT3 (SLC22A3) mRNA expression
(real time data).
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showed a higher SLC22A3 expression compared to HCC
with high SLC22A1 expression (p < 0.001), which is in
contrast to the physiological state with high SLC22A1
and low SLC22A3 expression. The importance of these
findings, especially with regard to tumor therapy needs
to be defined in future.
Although OCTs are functionally influenced by many
endogenous and exogenous substances, to date there are
no data about pathways and mechanisms of the
Table 3 Patients and tumor characteristics in dependence of the intratumoral OCT3 mRNA expression
Characteristics OCT3 (SLC22A3)
Low expression
(< Median)
OCT3 (SLC22A3)
High expression
(≥ Median)
P-value
N2 3 2 6
Median follow-up in days (range) 348 (22-1531) 423 (29-1645) n.s. (0.36)
Male/female (n) 21/2 22/4 n.s. (0.67)
Median age in years (range) 71 (35-84) 64 (47-93) n.s. (0.13)
1-3 nodules/multiple nodules (specimen) 16/7 18/8 n.s. (0.98)
Tumor diameter < 3 cm/> 3 cm 7/16 11/15 n.s. (0.55)
Median tumor diameter in cm (range) 5.0 (1.5-30) 4.4 (0.1-20) n.s. (0.98)
T classification: T1/T2/T3 (specimen) 6/9/8 10/11/5 n.s. (0.42)
Grading: G1/G2/G3/Gx 3/15/5/0 6/15/4/1 n.s. (0.60)
AFP > 100/< 100 * 4/17 7/19 n.s. (0.73)
Angioinvasion yes/no
# 3/18 7/17 n.s. (0.30)
Child A/B/C/no cirrhosis 11/0/1/11 7/4/5/10 n.s. (0.06)
Underlying disease (HCV/HBV/alcoholic/others/unknown) 5/2/2/6/8 4/6/2/8/6 n.s. (0.64)
SLC22A1 mRNA expression
ratio HCC/TST (range)
0.08
(0.001-1.36)
0.4
(0.003-2.78)
0.008
Pretreatment with chemoembolization (yes/no) 6/17 14/12 n.s. (0.08)
Liver transplantation/resection 6/17 13/13 n.s. (0.14)
Median: 0.658 * 2 unknown
# 4 unknown
Table 2 Patients and tumor characteristics in dependence of the intratumoral OCT1 mRNA expression
Characteristics OCT1 (SLC22A1)
Low expression
(< Median)
OCT1 (SLC22A1)
High expression
(≥ Median)
P-value
N2 7 2 6
Median follow-up in days (range) 434 (22-1538) 425 (109-1645) n.s. (0.20)
Male/female (n) 23/4 23/3 n.s. (1.00)
Median age in years (range) 69 (35-86) 67 (47-93) n.s. (0.35)
1-3 nodules/multiple nodules (specimen) 18/9 18/8 n.s. (1.00)
Tumor diameter < 3 cm/> 3 cm 5/22 14/12 0.010
Median tumor diameter in cm (range) 6.0 (1.5-30) 2.8 (0.1-20) 0.035
T classification: T1/T2/T3 (specimen) 8/7/12 10/13/3 0.025
Grading: G1/G2/G3/Gx 1/17/9/0 10/14/1/1 0.001
AFP > 100/< 100 * 9/16 2/24 0.019
Angioinvasion yes/no
# 7/16 4/22 n.s. (0.31)
Child A/B/C/no cirrhosis 10/1/1/15 9/3/6/8 n.s. (0.08)
Underlying disease (HCV/HBV/alcoholic/others/unknown) 4/2/1/10/10 6/7/3/5/5 n.s. (0.11)
SLC22A3 mRNA expression
ratio HCC/TST (range)
0.21
(0.001-3.07)
0.86
(0.33-3.12)
0.008
Pretreatment with chemoembolization (yes/no) 2/25 18/8 < 0.001
Liver transplantation/resection 4/23 16/10 0.001
Median: 0.112 * 2 unknown
# 4 unknown
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Page 7 of 10Figure 3 (A) RT-PCR analysis (- TST; + HCC) and Western blot analysis (B) of eleven patients with HCC and the corresponding TST.
Protein expression and downregulation of the transporters, especially OCT1, correlate well compared with the RT-PCR data. Stably transfected
cancer cell lines (pcDNA3_OCT1h) served as positive control for OCT1 (Pos.); (OCT1: 61kD; OCT3: 60kD). (C) Analysis of OCT1 protein
expression by immunofluorescence. OCT1 shows a membranous staining in normal liver tissue, whereas the protein is downregulated in HCC
(D). Tumor borders of two cases with downregulation of OCT1 in HCC (upper panel: case 2–Figure 3A/3B; lower panel: case 3–Figure 3A/3B).
There is a diffuse staining near the tumor border as well as in the tumor tissue (lower panel) suggesting that the transporter function is affected
in HCC.
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ters are located on the chromosomal locus 6q26-27 in a
conserved gene cluster and influenced by genomic
imprinting mechanisms involving the well known IGF2R
tumor suppressor gene [19,20]. This may contribute to
complex genetic and epigenetic regulations in the con-
text of human malignancy.
Interestingly, the OCTs could also be directly asso-
ciated with mechanisms of tumor development by influ-
ence of environmental factors and carcinogens. In
HepG2 cells expression of SLC22A3 correlates with the
carcinogenic potency after treatment with polycyclic
aromatic hydrocarbons (PAH), which are known to be
potential carcinogens [21].
Furthermore, OCTs may play an important role in the
therapy of malignant tumors. They are held responsible
for the cytotoxicity of platin derivatives and are predic-
tors of responses to small molecules [11,22-24]. Down-
regulation in HCC could be responsible for a worse or
lacking response towards platin treatment. In colorectal
cancer OCTs are determinants of oxaliplatin cytotoxicity
[11,25-27]. Moreover, SLC22A3 expression in renal cell
carcinoma cell lines enhances the sensitivity towards
chemotherapeutics as melphalan, irinotecan and vincris-
tin [28].
In patients with chronic myeloid leukaemia SLC22A1
expression is associated with treatment response to the
tyrosine kinase inhibitor (TKI) imatinib [13,22,29].
Another multi-tyrosine kinase inhibitor sorafenib, which
is used as systemic therapy in HCC, reduces the cellular
uptake of platin and the platin-induced cytotoxicity in
human colorectal cancer cell lines [30]. Recently, it has
been shown, that oxaliplatin uptake in CRC is attenu-
ated by the TKI saracatinib via inhibition of OCT2 [31].
These findings elucidate the crucial role of OCTs in dif-
ferent treatment protocols affecting classical chemother-
apeutics as platin derivatives as well as small molecules
like TKI. It is still unknown whether the presence of
OCTs in tumors is beneficial with regard to therapy or
deleterious by supporting tumor growth. Our data sug-
gest, that a downregulation of OCT1 in the liver with
possibly lacking function is associated with a worse out-
come regardless of TKI treatment, since none of our
patients has received a systemic therapy.
Whether OCTs are associated with treatment
response to Sorafenib has not been investigated yet. To
date, to the best of our knowledge, there exist no data
regarding the clinical, prognostic and therapeutical rele-
vance of OCTs in HCC. Because of the impact of OCT1
on tumor characteristics and patient survival we focused
on this transporter on protein level. The relevance of
OCT3 needs to be further investigated. Future studies
will be necessary to evaluate possible diagnostic and
therapeutic consequences.
Conclusions
Downregulation of OCT1 (SLC22A1) expression in HCC
is associated with advanced tumor stages and a worse
patient survival. These findings could be important for
treatment options.
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